{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T21:28:26Z","timestamp":1773091706131,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,6,1]]},"DOI":"10.1093\/jjco\/hyl052","type":"journal-article","created":{"date-parts":[[2006,7,5]],"date-time":"2006-07-05T16:20:19Z","timestamp":1152116419000},"page":"337-343","source":"Crossref","is-referenced-by-count":121,"title":["Von Hippel\u2013Lindau Disease: Molecular Pathological Basis, Clinical Criteria, Genetic Testing, Clinical Features of Tumors and Treatment"],"prefix":"10.1093","volume":"36","author":[{"given":"Taro","family":"Shuin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ichiro","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiwa","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutsuo","family":"Furihata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Ashida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,6]]},"reference":[{"key":"key\n\t\t\t\t20171013024157_B1","doi-asserted-by":"crossref","unstructured":"Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science1993;260:1317\u201320.","DOI":"10.1126\/science.8493574"},{"key":"key\n\t\t\t\t20171013024157_B2","doi-asserted-by":"crossref","unstructured":"Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer2002;2:673\u201382.","DOI":"10.1038\/nrc885"},{"key":"key\n\t\t\t\t20171013024157_B3","doi-asserted-by":"crossref","unstructured":"Von Hippel E. Die anatomische Grund lage der von mir beschriebenen \u2018sehr seltenen Erkrankung der Netzhaut\u2019. Graefes Arch Ophthalmol1911;79:350\u201377.","DOI":"10.1007\/BF01966371"},{"key":"key\n\t\t\t\t20171013024157_B4","unstructured":"Lindau A. Studien uber Kleinhirncysten. Bau, Pathogenese und Bezoejimgem zur Angiomatosis retinae. Acta Pathol Microbiol Scand1926;(Suppl 1):1\u2013128."},{"key":"key\n\t\t\t\t20171013024157_B5","doi-asserted-by":"crossref","unstructured":"Melmon KL, Rosen SW. Lindau's disease. Am J Med1964;36:595\u2013617.","DOI":"10.1016\/0002-9343(64)90107-X"},{"key":"key\n\t\t\t\t20171013024157_B6","doi-asserted-by":"crossref","unstructured":"Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DY, Lee S, et al. Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta1996;1242:201\u201310.","DOI":"10.1016\/0304-419X(95)00012-5"},{"key":"key\n\t\t\t\t20171013024157_B7","doi-asserted-by":"crossref","unstructured":"Hergovich A, Lisztwan J, Barry R, Ballschmieter P, Krek W. Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL. Nat Cell Biol2003;5:64\u201370.","DOI":"10.1038\/ncb899"},{"key":"key\n\t\t\t\t20171013024157_B8","doi-asserted-by":"crossref","unstructured":"Okuda H, Saitoh K, Hirai S, Iwai K, Takaki Y, Shuin T, et al. The von Hippel-Lindau tumor suppressor protein mediates ubiquitination of activated atypical protein kinase C. J Biol Chem2001;276:43611\u20137.","DOI":"10.1074\/jbc.M107880200"},{"key":"key\n\t\t\t\t20171013024157_B9","doi-asserted-by":"crossref","unstructured":"Kaelin WG Jr. The von Hippel-Lindau gene, kidney cancer, and oxygen sensing. J Am Soc Nephrol2003;14:2703\u201311.","DOI":"10.1097\/01.ASN.0000092803.69761.41"},{"key":"key\n\t\t\t\t20171013024157_B10","doi-asserted-by":"crossref","unstructured":"Schnell PO, Ignacak ML, Bauer AL, Striet JB, Paulding WR, Czyzyk-Krzeska MF. Regulation of tyrosine hydroxylase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors. J Neurochem2003;85:483\u201391.","DOI":"10.1046\/j.1471-4159.2003.01696.x"},{"key":"key\n\t\t\t\t20171013024157_B11","doi-asserted-by":"crossref","unstructured":"Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial Pheo genes: developmental culling and cancer. Cancer Cell2005;8:155\u201367.","DOI":"10.1016\/j.ccr.2005.06.015"},{"key":"key\n\t\t\t\t20171013024157_B12","doi-asserted-by":"crossref","unstructured":"Lonser RR, Glenn GM, Walther M, Chew EY, Libutti SK, Linehan WM, et al. Von Hippel-Lindau disease. The Lancet2003;361:2059\u201367.","DOI":"10.1016\/S0140-6736(03)13643-4"},{"key":"key\n\t\t\t\t20171013024157_B13","doi-asserted-by":"crossref","unstructured":"Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet2002;32:614\u201321.","DOI":"10.1038\/ng1019"},{"key":"key\n\t\t\t\t20171013024157_B14","doi-asserted-by":"crossref","unstructured":"Hammel PR, Vilgrain V, Terris B, Penfornis A, Sauvanet A, Correas JM, et al. Pancreatic involvement in von Hippel-Lindau disease. The Groupe Francophone d'Etude de la Maladie de von Hippel-Lindau. Gastroenterology2000;119:1087\u201395.","DOI":"10.1053\/gast.2000.18143"},{"key":"key\n\t\t\t\t20171013024157_B15","doi-asserted-by":"crossref","unstructured":"Hernberg M, Virkkunen P, Bono P, Ahtinen H, Maenpaa H, Joensuu H. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol2003;21:3770\u20136.","DOI":"10.1200\/JCO.2003.01.536"},{"key":"key\n\t\t\t\t20171013024157_B16","doi-asserted-by":"crossref","unstructured":"Lara PN Jr, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, et al. The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial. Clin Cancer Res2005;9:4772\u201381.","DOI":"10.1158\/1078-0432.CCR-04-2602"},{"key":"key\n\t\t\t\t20171013024157_B17","unstructured":"Michaelson MD, Redman BG, Hudes GR, Wilding G, Rini BI, George DJ, et al. Phase 2 trials of SU11248 show antitumor activity in second-line therapy for patients with metastatic renal cell carcinoma (RCC). 2005 ASCO Annual Meeting, May 13\u201317, 2005, Orlando, FL."},{"key":"key\n\t\t\t\t20171013024157_B18","doi-asserted-by":"crossref","unstructured":"Rini B, Rixe O, Bukowski R, Michaelson MD, Wilding G, Hudes G, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). 2005 ASCO Annual Meeting, May 13\u201317, 2005, Orlando, FL.","DOI":"10.1200\/jco.2005.23.16_suppl.4509"},{"key":"key\n\t\t\t\t20171013024157_B19","unstructured":"Web site of VHL family alliance in America: http:\/\/www.vhl.org\/, in Japan. http:\/\/www1.odn.ne.jp\/vhl_japan\/"},{"key":"key\n\t\t\t\t20171013024157_B20","unstructured":"Web site of Department of Urology, Kochi University, School of Medicine. http:\/\/www.kochi-ms.ac.jp\/\u223cfm_urol\/japanese\/vhl.htm."}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/36\/6\/337\/5166675\/hyl052.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T16:26:46Z","timestamp":1555691206000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jjco\/article\/36\/6\/337\/901485\/Von-HippelLindau-Disease-Molecular-Pathological"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,1]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2006,6]]},"published-print":{"date-parts":[[2006,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyl052","relation":{},"ISSN":["1465-3621","0368-2811"],"issn-type":[{"value":"1465-3621","type":"electronic"},{"value":"0368-2811","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,6]]},"published":{"date-parts":[[2006,6,1]]}}}